Skip to main content

Table 2 Univariable logistic regression for associations between socio-demographics, CD4 and cART with anal HPV infection among HIV-positive males in Taizhou, China

From: Increased CD4+ T cell count is associated with lower anal human papillomavirus prevalence among HIV-positive male cohort in Taizhou, China: a cross-sectional study

 

Any HPV

Any HR-HPV

Any LR-HPV

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

Age(years)

      

 18–24

1.00

 

1.00

 

1.00

 

 25–34

0.94 (0.44, 2.01)

0.869

0.75 (0.35, 1.60)

0.454

1.66 (0.70, 3.94)

0.251

 35–44

0.63 (0.29, 1.35)

0.232

0.53 (0.25, 1.13)

0.100

0.83 (0.34, 2.02)

0.687

 45–54

0.80 (0.38, 1.68)

0.551

0.68 (0.33, 1.43)

0.312

0.92 (0.39, 2.18)

0.852

 55–82

0.47 (0.22, 0.99)

0.046

0.32 (0.15, 0.67)

0.003

0.50 (0.21, 1.21)

0.124

Level of education

      

 Illiterate or primary school

1.00

 

1.00

 

1.00

 

 Middle school

1.57 (1.10, 2.24)

0.012

2.03 (1.40, 2.96)

 < 0.001

2.66 (1.64, 4.33)

 < 0.001

 High school

1.59 (1.03, 2.44)

0.036

2.16 (1.38, 3.38)

 < 0.001

2.39 (1.35, 4.22)

0.003

 College or above

2.01 (1.20, 3.37)

0.008

2.34 (1.38, 3.96)

0.002

3.39 (1.82, 6.33)

 < 0.001

Marital status

      

 Never married

1.00

 

1.00

 

1.00

 

 Currently married

0.56 (0.40, 0.77)

 < 0.001

0.50 (0.36, 0.69)

 < 0.001

0.51 (0.35, 0.74)

 < 0.001

 Widowed/divorced

0.70 (0.46, 1.06)

0.091

0.80 (0.53, 1.22)

0.302

0.62 (0.38, 1.01)

0.056

Smoking amount (packyear)

      

 0

1.00

 

1.00

 

1.00

 

 0–20

0.85 (0.59, 1.25)

0.413

0.71 (0.48, 1.05)

0.088

0.82 (0.52, 1.29)

0.384

  > 20

0.44 (0.28, 0.68)

 < 0.001

0.44 (0.28, 0.70)

 < 0.001

0.44 (0.24, 0.80)

0.007

Alcohol consumption

      

 Drank≤once/month

1.00

 

1.00

 

1.00

 

 Drank > once/month

0.69 (0.50, 0.95)

0.022

0.59 (0.42, 0.82)

0.002

0.74 (0.49, 1.10)

0.132

Sexual orientation

      

 Hetero-sexual

1.00

 

1.00

 

1.00

 

 Homo-sexual

2.28 (1.66, 3.13)

 < 0.001

3.28 (2.36, 4.54)

 < 0.001

4.16 (2.82, 6.13)

 < 0.001

 Bi-sexual or uncertain

2.58 (1.58, 4.20)

 < 0.001

3.78 (2.32, 6.17)

 < 0.001

2.90 (1.66, 5.07)

 < 0.001

Self-reported history of STIs

      

 No

1.00

 

1.00

 

1.00

 

 Yes

1.41 (1.00, 1.98)

0.048

1.60 (1.14, 2.25)

0.007

1.67 (1.14, 2.46)

0.009

Multiple sex partnersa

      

 No

1.00

 

1.00

 

1.00

 

 Yes

0.92 (0.51, 1.64)

0.770

0.91 (0.51, 1.64)

0.753

0.59 (0.32, 1.09)

0.093

Condom usea

      

 Yes

1.00

 

1.00

 

1.00

 

 No

0.13 (0.02, 1.09)

0.060

0.10 (0.01, 0.77)

0.028

0.29 (0.07, 1.16)

0.080

Baseline CD4+ T (cells/µL)

      

  < 200

1.00

 

1.00

 

1.00

 

 200–349

1.06 (0.76, 1.47)

0.732

1.11 (0.79, 1.55)

0.555

1.05 (0.70, 1.56)

0.815

 350–499

0.95 (0.62, 1.47)

0.819

1.05 (0.68, 1.63)

0.833

1.24 (0.75, 2.07)

0.399

  ≥ 500

1.20 (0.69, 2.09)

0.523

1.09 (0.62, 1.93)

0.760

1.01 (0.51, 2.00)

0.975

Current CD4+ T (cells/µL)

      

  < 200

1.00

 

1.00

 

1.00

 

 200–349

0.77 (0.46, 1.29)

0.320

0.55 (0.33, 0.91)

0.020

0.95 (0.52, 1.72)

0.862

 350–499

0.54 (0.32, 0.91)

0.021

0.57 (0.34, 0.95)

0.032

0.83 (0.45, 1.52)

0.541

  ≥ 500

0.64 (0.39, 1.03)

0.067

0.56 (0.35, 0.92)

0.020

1.01 (0.58, 1.78)

0.968

Change of CD4+ T (cells/µL)b

      

 Decreased or unchanged

1.00

 

1.00

 

1.00

 

 Increased

0.67 (0.46, 0.97)

0.034

0.73 (0.50, 1.06)

0.094

1.14 (0.72, 1.80)

0.578

cART

      

 EFV + 3TC + TDF

1.00

 

1.00

 

1.00

 

 EFV + 3TC + AZT

0.95 (0.66, 1.35)

0.763

1.08 (0.75, 1.54)

0.693

1.14 (0.75, 1.72)

0.540

 NVP + 3TC + AZT

0.75 (0.50, 1.12)

0.162

0.70 (0.46, 1.08)

0.107

0.63 (0.36, 1.08)

0.094

 Others combined

0.73 (0.43, 1.25)

0.251

0.83 (0.48, 1.44)

0.512

1.33 (0.73, 2.41)

0.353

Duration of cART (years)

      

  < 2

1.00

 

1.00

 

1.00

 

  2– < 5

0.75 (0.54, 1.04)

0.082

0.79 (0.56, 1.10)

0.161

0.80 (0.54, 1.18)

0.254

  ≥ 5

0.58 (0.40, 0.85)

0.006

0.58 (0.40, 0.86)

0.007

0.67 (0.42, 1.06)

0.089

  1. cART combined antiretroviral therapy (741 participants were under cART), EFV Efavirenz, 3TC Lamivudine, TDF Tenofovir, AZT Zidovudine, NVP Nevirapine
  2. aLife-time multiple sex partners; condom use in the last 6 months
  3. bThe change of CD4 + T cell counts was calculated by current CD4 minus baseline CD4. If the result was positive, it was defined as “increased CD4 + T cell counts”; and if the result was negative or zero, it was defined as “decreased or unchanged CD4 + T cell counts”
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us